Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.
Box HJ, Sharp J, Pennington SH, Kijak E, Tatham L, Caygill CH, Lopeman RC, Jeffreys LN, Herriott J, Neary M, Valentijn A, Pertinez H, Curley P, Arshad U, Rajoli RKR, Jochmans D, Vangeel L, Neyts J, Chatelain E, Escudié F, Scandale I, Rannard S, Stewart JP, Biagini GA, Owen A. Box HJ, et al. Among authors: kijak e. J Antimicrob Chemother. 2024 Jan 3;79(1):172-178. doi: 10.1093/jac/dkad362. J Antimicrob Chemother. 2024. PMID: 37995258 Free PMC article.
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.
Neary M, Sharp J, Gallardo-Toledo E, Herriott J, Kijak E, Bramwell C, Cox H, Tatham L, Box H, Curley P, Arshad U, Rajoli RKR, Pertinez H, Valentijn A, Dhaliwal K, Mc Caughan F, Hobson J, Rannard S, Kipar A, Stewart JP, Owen A. Neary M, et al. Among authors: kijak e. Viruses. 2023 Aug 15;15(8):1744. doi: 10.3390/v15081744. Viruses. 2023. PMID: 37632086 Free PMC article.
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2.
Gaynor KU, Vaysburd M, Harman MAJ, Albecka A, Jeffrey P, Beswick P, Papa G, Chen L, Mallery D, McGuinness B, Van Rietschoten K, Stanway S, Brear P, Lulla A, Ciazynska K, Chang VT, Sharp J, Neary M, Box H, Herriott J, Kijak E, Tatham L, Bentley EG, Sharma P, Kirby A, Han X, Stewart JP, Owen A, Briggs JAG, Hyvönen M, Skynner MJ, James LC. Gaynor KU, et al. Among authors: kijak e. Nat Commun. 2023 Jun 16;14(1):3583. doi: 10.1038/s41467-023-39158-1. Nat Commun. 2023. PMID: 37328472 Free PMC article.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G, Wang L, Griffiths C, Brown ML, Scott WE 3rd, Pereyra-Gerber P, Gelson WTH, Brown S, Dillon S, Muraro D, Sharp J, Neary M, Box H, Tatham L, Stewart J, Curley P, Pertinez H, Forrest S, Mlcochova P, Varankar SS, Darvish-Damavandi M, Mulcahy VL, Kuc RE, Williams TL, Heslop JA, Rossetti D, Tysoe OC, Galanakis V, Vila-Gonzalez M, Crozier TWM, Bargehr J, Sinha S, Upponi SS, Fear C, Swift L, Saeb-Parsy K, Davies SE, Wester A, Hagström H, Melum E, Clements D, Humphreys P, Herriott J, Kijak E, Cox H, Bramwell C, Valentijn A, Illingworth CJR; UK-PBC Consortium; Dahman B, Bastaich DR, Ferreira RD, Marjot T, Barnes E, Moon AM, Barritt AS 4th, Gupta RK, Baker S, Davenport AP, Corbett G, Gorgoulis VG, Buczacki SJA, Lee JH, Matheson NJ, Trauner M, Fisher AJ, Gibbs P, Butler AJ, Watson CJE, Mells GF, Dougan G, Owen A, Lohse AW, Vallier L, Sampaziotis F. Brevini T, et al. Among authors: kijak e. Nature. 2023 Mar;615(7950):134-142. doi: 10.1038/s41586-022-05594-0. Epub 2022 Dec 5. Nature. 2023. PMID: 36470304 Free PMC article.
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
Box H, Pennington SH, Kijak E, Tatham L, Caygill CH, Lopeman RC, Jeffreys LN, Herriott J, Sharp J, Neary M, Valentijn A, Pertinez H, Curley P, Arshad U, Rajoli RK, Rannard S, Stewart JP, Biagini GA, Owen A. Box H, et al. Among authors: kijak e. bioRxiv [Preprint]. 2022 Mar 3:2022.03.03.482788. doi: 10.1101/2022.03.03.482788. bioRxiv. 2022. PMID: 35262084 Free PMC article. Preprint.
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
Tatham L, Kipar A, Sharp J, Kijak E, Herriott J, Neary M, Box H, Toledo EG, Valentijn A, Cox H, Pertinez H, Curley P, Arshad U, Rajoli RK, Rannard S, Stewart J, Owen A. Tatham L, et al. Among authors: kijak e. bioRxiv [Preprint]. 2023 Mar 9:2022.01.23.477397. doi: 10.1101/2022.01.23.477397. bioRxiv. 2023. PMID: 35118468 Free PMC article. Preprint.
33 results